(1) van Spronsen FJ, van Wegberg AM, Ahring K, Bélanger-Quintana A, Blau N, Bosch AM, et al. Key European guidelines for the diagnosis and management of patients with phenylketonuria. Lancet Diabetes Endocrinol. 2017;5(9):743-756.
(2) van Wegberg, AM, MacDonald A, Ahring K, Bélanger-Quintana A, Blau N, Bosch AM, et al. The complete European guidelines on phenylketonuria: diagnosis and treatment. Orphanet J Rare Dis. 2017;12(1):162.
(3) Luciana M, Sullivan J, Nelson CA. Associations between phenylalanine-to-tyrosine ratios and performance on tests of neuropsychological function in adolescents treated early and continuously for phenylketonuria. Child Dev. 2001;72(6):1637-1652.
(4) Chinsky JM, Singh R, Ficicioglu C, van Karnebeek, CD, Grompe M, Mitchell G, et al. Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations. Genet Med. 2017;19(12).
(5) van Vliet D, van Dam E, van Rijn M, Derks TG, Venema-Liefaard G, Hitzert MM, et al. Infants with Tyrosinemia Type 1: Should phenylalanine be supplemented? JIMD Rep. 2015;18:117-124.
(6) García MI, de la Parra A, Arias C, Arredondo M, Cabello JF. Long-term cognitive functioning in individuals with tyrosinemia type 1 treated with nitisinone and protein-restricted diet. Mol Genet Metab Rep. 2017;11:12-16.
(7) van Ginkel WG, van Vliet D, Burgerhof JG, de Blaauw P, Rubio Gozalbo ME, Heiner-Fokkema MR, et al. Presumptive brain influx of large neutral amino acids and the effect of phenylalanine supplementation in patients with Tyrosinemia type 1. PLoS ONE. 2017;12(9):e0185342.
(8) Walker H, Pitkanen M, Rahman Y, Barrington SF. Three Cases of Hereditary Tyrosinaemia Type 1: Neuropsychiatric Outcomes and Brain Imaging Following Treatment with NTBC. JIMD Rep. 2018;40:97-103.
(9) Stroup BM, Held PK, Williams P, Clayton MK, Murali SG, Rice GM, et al. Clinical relevance of the discrepancy in phenylalanine concentrations analyzed using tandem mass spectrometry compared with ion-exchange chromatography in phenylketonuria. Mol Genet Metab Rep. 2016;6:21-26.
(10) Allard P, Cowell LD, Zytkovicz TH, Korson MS, Ampola MG. Determination of phenylalanine and tyrosine in dried blood specimens by ion-exchange chromatography using the Hitachi L-8800 analyzer. Clin Biochem. 2004;37(10):857-862.
(11) Gregory CO, Yu C, Singh RH. Blood phenylalanine monitoring for dietary compliance among patients with phenylketonuria: comparison of methods. Genet Med. 2007;9(11):761-765.
(12) Groselj U, Murko S, Tansek MZ, Kovac J, Bakija AT, Lampret BR, et al. Comparison of tandem mass spectrometry and amino acid analyzer for phenylalanine and tyrosine monitoring--implications for clinical management of patients with hyperphenylalaninemia. Clin Biochem. 2015;48(1-2):14-18.
(13) Daly A, Gokmen-Ozel H, MacDonald A, Preece MA, Davies P, Chakrapani A, et al. Diurnal variation of phenylalanine concentrations in tyrosinaemia type 1: should we be concerned? J Hum Nutr Diet. 2012;25(2):111-116.
(14) van Dam E, Daly A, Venema-Liefaard G, van Rijn M, Derks TG, McKiernan PJ, et al. What Is the Best Blood Sampling Time for Metabolic Control of Phenylalanine and Tyrosine Concentrations in Tyrosinemia Type 1 Patients? JIMD Rep. 2017;36:49-57.
(15) van Spronsen FJ, van Dijk T, Smit GP, van Rijn M, Reijngoud DJ, Berger R, et al. Large daily fluctuations in plasma tyrosine in treated patients with phenylketonuria. Am J Clin Nutr. 1996;64(6):916-921.
(16) van Rijn M, Hoeksma M, Sauer PJ, Modderman P, Reijngoud D, van Spronsen FJ. Diurnal variations in blood phenylalanine of PKU infants under different feeding regimes. Mol Genet Metab. 2011;104 Suppl:68.
(17) Takehana S, Yoshida H, Ozawa S, Yamazaki J, Shimbo K, Nakayama A, et al. The effects of pre-analysis sample handling on human plasma amino acid concentrations. Clin Chim Acta. 2016;455:68-74.
(18) van Vliet D, Bruinenberg VM, Mazzola PN, van Faassen MH, de Blaauw P, Kema IP, et al. Large Neutral Amino Acid Supplementation Exerts Its Effect through Three Synergistic Mechanisms: Proof of Principle in Phenylketonuria Mice. PLoS ONE. 2015;10(12):e0143833.
(19) Clinical and Laboratory Standards Institute (CLSI). EP09-A3: Measurement Procedure Comparison and Bias Estimation Using Patient Samples, 3rd Edition. CLSI 2013.
(20) Bilić-Zulle L. Comparison of methods: Passing and Bablok regression. Biochem Med (Zagreb). 2011;21(1):49-52.
(21) Rouse BM. Phenylalanine deficiency syndrome. J Pediatr. 1966;69(2):246-249.
(22) Zori R, Thomas JA, Shur N, Rizzo WB, Decker C, Rosen O, et al. Induction, titration, and maintenance dosing regimen in a phase 2 study of pegvaliase for control of blood phenylalanine in adults with phenylketonuria. Mol Genet Metab. 2018;125(3):217-227.
(23) Longo N, Harding CO, Burton BK, Grange DK, Vockley J, Wasserstein M, et al. Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial. Lancet. 2014;384(9937):37-44.
(24) Wagner M, Tonoli D, Varesio E, Hopfgartner G. The use of mass spectrometry to analyze dried blood spots. Mass Spectrom Rev. 2016;35(3):361-438.
(25) Lawson AJ, Bernstone L, Hall SK. Newborn screening blood spot analysis in the UK: influence of spot size, punch location and haematocrit. J Med Screen. 2016;23(1):7-16.
(26) Ceglarek U, Müller P, Stach B, Bührdel P, Thiery J, Kiess W. Validation of the phenylalanine/tyrosine ratio determined by tandem mass spectrometry: sensitive newborn screening for phenylketonuria. Clin Chem Lab Med. 2002;40(7):693-697.
(27) Keevil BG. The analysis of dried blood spot samples using liquid chromatography tandem mass spectrometry. Clin Biochem. 2011;44(1):110-118.
(28) Adam BW, Alexander JR, Smith SJ, Chace DH, Loeber JG, Elvers LH, et al. Recoveries of phenylalanine from two sets of dried-blood-spot reference materials: prediction from hematocrit, spot volume, and paper matrix. Clin Chem. 2000;46(1):126-128.